{
  "denotations": [
    {
      "id": "T1",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 40,
        "end": 46
      }
    },
    {
      "id": "T2",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 61,
        "end": 67
      }
    },
    {
      "id": "T3",
      "obj": "Chemical",
      "span": {
        "begin": 132,
        "end": 138
      }
    },
    {
      "id": "T4",
      "obj": "Chemical",
      "span": {
        "begin": 144,
        "end": 152
      }
    },
    {
      "id": "T5",
      "obj": "Chemical",
      "span": {
        "begin": 183,
        "end": 191
      }
    },
    {
      "id": "T6",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 214,
        "end": 220
      }
    },
    {
      "id": "T7",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 235,
        "end": 241
      }
    }
  ],
  "sourcedb": "PubMed",
  "sourceid": "22735459_10",
  "text": "CONCLUSION : These results suggest that CYP2C9 * 1 / * 3 and CYP2C9 * 1 / * 13 are similarly associated with decreased formation of E-3174 from losartan , but the clinical effects of losartan may not be reduced by CYP2C9 * 1 / * 3 and CYP2C9 * 1 / * 13 ."
}
